SCHEMBL14784331

SCHEMBL14784331

O=C(O)N1CCN(c2cnc3ccc(OCc4ccccc4)cc3c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
AKR1C3 P42330 1/20 0.48
SLC6A7 Q99884 1/20 0.47
MEN1 O00255 1/20 0.46
HSP90AA1 P07900 1/20 0.46
KMT2A Q03164 1/20 0.46
NMT1 P30419 2/20 0.46
CCKAR P32238 3/20 0.45
MGLL Q99685 2/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
NMT2 O60551 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
HTT P42858 1/20 0.43
PRMT5 O14744 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14783422 0.96 NMT1 (0.47) MAPTAKR1C3SLC6A7MEN1HSP90AA1
SCHEMBL14784083 0.89 RAB9A (0.49) MAPTMEN1HSP90AA1KMT2AALDH1A1
SCHEMBL14784224 0.83 MET (0.52) AKR1C3NMT1KDM4EALDH1A1NMT2
SCHEMBL14783745 0.83 ADAMTS5 (0.46) MAPTMEN1HSP90AA1KMT2ANMT1
SCHEMBL17061423 0.83 F10 (0.46) MAPTMEN1HSP90AA1KMT2ANMT1
SCHEMBL14783723 0.82 HTR3A (0.56) MAPTKMT2ANPC1RAB9APRMT5
SCHEMBL6415146 0.82 SLC6A7 (0.50) MAPTSLC6A7KMT2AKDM4EALDH1A1
SCHEMBL14784551 0.81 MEN1 (0.45) MEN1HSP90AA1KMT2ANMT1NMT2
SCHEMBL14783746 0.81 CACNA1B (0.46) MAPTMEN1HSP90AA1KMT2ANMT1
SCHEMBL14783548 0.80 HRH3 (0.56) PDE3BPDE3APRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2755976-B1 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2018-07-18 EP disclosed
US-9474762-B2 Triazolopyridine compounds NOVARTIS AG (CH) 2016-10-25 US disclosed
US-20150250799-A1 Triazolopyridine Compounds NOVARTIS AG (CH) 2015-09-10 US disclosed
US-9062045-B2 Triazolopyridine compounds NOVARTIS AG (CH) 2015-06-23 US disclosed
EP-2755976-A1 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4]TRIAZOLO [4, 3 -A]PYRADINES AS TYROSINE KINASE Novartis AG (CH) 2014-07-23 EP disclosed
US-20130245002-A1 Triazolopyridine Compounds NOVARTIS AG (CH) 2013-09-19 US disclosed
WO-2013038362-A1 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE NOVARTIS AG (CH) 2013-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150250799-A1 Triazolopyridine Compounds FLT3, RET, MET MAPT 1866/4885AKR1C3 2950/4885SLC6A7 2449/4885
US-20130245002-A1 Triazolopyridine Compounds FLT3, RET, MET MAPT 1866/4885AKR1C3 2950/4885SLC6A7 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.